Literature DB >> 2421109

Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies.

M C Bird, A G Bosanquet, S Forskitt, E D Gilby.   

Abstract

A semi-micro differential staining cytotoxicity (micro-DiSC) assay has been developed to determine the in-vitro chemosensitivity of haematological cancers. The method comprised isolation of leukocytes from blood or bone marrow, drug exposure and culture for 4 days in 1 ml tubes arranged in the microtitre format. Drug-induced tumour cell kill was determined by differential staining of live and dead cells, such that the former could be morphologically identified. Tumour cell viability was calculated by reference to an internal standard of fixed duck red blood cells. Up to 15 drugs at 5-6 concentrations each could be set up at a time in the assay within one hour of receipt of a sample, using only 10(7) viable cells. A result was obtained in 38 of 40 samples received. The assay is of potential use for the routine prediction of clinical response to cytotoxic drugs in haematological cancers and warrants wider investigation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421109     DOI: 10.1016/0145-2126(86)90075-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  18 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues.

Authors:  R A Nagourney; J C Messenger; D H Kern; L M Weisenthal
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours.

Authors:  A G Bosanquet; S Forskitt
Journal:  Cytotechnology       Date:  1989-08       Impact factor: 2.058

5.  Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.

Authors:  Leonardo Luís Artico; Angelo Brunelli Albertoni Laranjeira; Livia Weijenborg Campos; Juliana Ronchi Corrêa; Priscila Pini Zenatti; José Barreto Campello Carvalheira; Sandra Regina Brambilla; Alexandre Eduardo Nowill; Silvia Regina Brandalise; José Andrés Yunes
Journal:  Blood Adv       Date:  2021-09-28

6.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

7.  Chlorambucil: stability of solutions during preparation and storage.

Authors:  A G Bosanquet; H E Clarke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.

Authors:  J Kristensen; B Jonsson; C Sundström; P Nygren; R Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

9.  Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan.

Authors:  A G Bosanquet; A R Burlton
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

Review 10.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.